Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jan 14;10(2):631-642.
doi: 10.12998/wjcc.v10.i2.631.

Malignant solitary fibrous tumor in the central nervous system treated with surgery, radiotherapy and anlotinib: A case report

Dong-Yong Zhang  1 , Lan Su  2 , Yi-Wei Wang  3
Affiliations
Case Reports

Malignant solitary fibrous tumor in the central nervous system treated with surgery, radiotherapy and anlotinib: A case report

Dong-Yong Zhang et al. World J Clin Cases. .

Abstract

Background: Solitary fibrous tumor (SFT) of the central nervous system is rare. It is predominantly benign and rarely malignant. There is no established standardized treatment regimen for malignant intracranial SFTs.

Case summary: We present a rare case of SFT in a 9-year-old girl with a space-occupying effect in the frontal-parietal lobes. She underwent craniotomy, and the mass was resected. Immunohistochemistry examination of the specimen showed that Ki-67 proliferation index staining was highly positive in 80% of tumor cells. Whole exome sequencing of the surgical tissue showed 38 somatic gene mutations and 1 gene amplification such as fibroblast growth factor receptor 4 or TP53. At 1.5 mo after surgery, head magnetic resonance imaging revealed that the tumor had recurred. The patient received 60 Gy and 30 fractions of intensity modulated radiotherapy. The patient then received anlotinib 8 mg po qd for 1-14 d of a 21 d cycle. Following this regimen, the patient achieved stable disease for > 17 mo. Magnetic resonance imaging at 1.5 year after surgery showed that the tumor had not progressed.

Conclusion: This is the first reported case of SFT of the central nervous system treated with surgery, radiotherapy and anlotinib. This regimen may be an effective treatment option for malignant intracranial SFT patients.

Keywords: Anlotinib; Biological therapy; Case report; Mutation; Recurrence; Sequence analysis.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare that they have no competing interest.

Figures

Figure 1
Figure 1
Treatment timeline and radiography. A: The treatment timeline; B: A head computed tomography scan revealed a quasi-circular mass in the left frontal-parietal region with high-density and associated hemorrhage. Brain magnetic resonance imaging (MRI) revealed low signals on T1 weighted imaging with high surrounding signals. High signals on T2 weighted imaging with low surrounding signals were observed, with marked enhancement on contrast measuring 4.8 cm × 5.0 cm × 4.5 cm in the left motor area of the frontal-parietal lobes (axial, sagittal and coronal views); C: Gadolinium-enhanced MRI imaging in axial, sagittal and coronal views 1 mo after surgery. MRI imaging showed no residual tumor; 1.5 mo after surgery, MRI imaging showed a solid mass. Five months and 1.5 year after surgery, MRI imaging showed that the tumor had not progressed. MRI + C: Gadolinium-enhanced magnetic resonance imaging.
Figure 2
Figure 2
Hematoxylin and eosin staining and immunohistochemistry examination of the specimen. A: Hematoxylin and eosin staining showed that a large number of spindle or oval cells were diffusely distributed, with deep staining of a null, “staghorn” vascular pattern, hypercellularity and increased mitotic activity were observed in the tumor (> 4 mitosis/10 high-power fields). Hematoxylin and eosin, 100 ×; B: Hematoxylin and eosin staining, 400 ×; C: Positive for CD99, 200 ×; D: Positive for Bcl-2, 200 ×; E: Positive for TP53, 200 ×; F: Positive for IDH1, 200 ×; G: Positive for TLE-1, 200 ×; H: Positive for vimentin, 200 ×; I: High Ki-67 proliferation index: 80%, 200 ×; J: Negative for CD34, 200 ×; K: Negative for STAT6, 200 ×; L: Negative for S100, 200 ×.
Figure 3
Figure 3
Circos 2D track plot of somatic variant across chromosomes in solitary fibrous tumor. In the inner ring, black denotes missense mutation, blue denotes frameshift mutation, and red denotes gene amplification.
See this image and copyright information in PMC

References

    1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803–820. - PubMed
    1. Carneiro SS, Scheithauer BW, Nascimento AG, Hirose T, Davis DH. Solitary fibrous tumor of the meninges: a lesion distinct from fibrous meningioma. A clinicopathologic and immunohistochemical study. Am J Clin Pathol. 1996;106:217–224. - PubMed
    1. Giordan E, Marton E, Wennberg AM, Guerriero A, Canova G. A review of solitary fibrous tumor/hemangiopericytoma tumor and a comparison of risk factors for recurrence, metastases, and death among patients with spinal and intracranial tumors. Neurosurg Rev. 2021;44:1299–1312. - PubMed
    1. Tani E, Wejde J, Åström K, Wingmo IL, Larsson O, Haglund F. FNA cytology of solitary fibrous tumors and the diagnostic value of STAT6 immunocytochemistry. Cancer Cytopathol. 2018;126:36–43. - PubMed
    1. Fritchie K, Jensch K, Moskalev EA, Caron A, Jenkins S, Link M, Brown PD, Rodriguez FJ, Guajardo A, Brat D, Velázquez Vega JE, Perry A, Wu A, Raleigh DR, Santagata S, Louis DN, Brastianos PK, Kaplan A, Alexander BM, Rossi S, Ferrarese F, Haller F, Giannini C. The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. Acta Neuropathol. 2019;137:307–319. - PMC - PubMed

Publication types